A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care
Fiona A. Miller,Robin Z. Hayeems,Jessica P. Bytautas,Philippe L. Bedard,Scott Ernst,Hal W. Hirte,Sebastien J. Hotte,Amit M. Oza,Albiruni Ryan Abdul Razak,Stephen Welch,Eric Winquist,Janet Dancey,Lillian L. Siu +12 more
TL;DR: The need for information and decision tools to support physicians in communicating realistic prospects of benefit and for cautious approaches to the generation of incidental genetic information is suggested.
Journal ArticleDOI
Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status.
Shao Hui Huang,Brian O'Sullivan,Wei Xu,Helen Zhao,Duoduo Chen,Jolie Ringash,Andrew Hope,Albiruni Ryan Abdul Razak,Ralph W. Gilbert,Jonathan C. Irish,John Kim,Laura A. Dawson,Andrew Bayley,B.C. John Cho,David P. Goldstein,Patrick J. Gullane,Eugene Yu,Bayardo Perez-Ordonez,Ilan Weinreb,John Waldron +19 more
TL;DR: HP(+) LNs involute more quickly than HPV(-) LNs but undergo a more prolonged process to eventual CR beyond the time of initial assessment at 8 to 12 weeks after treatment, which may be avoided for selected non-CR N2 HPV(+) cases with a significant LN involution.
Journal ArticleDOI
Promising SINEs for Embargoing Nuclear–Cytoplasmic Export as an Anticancer Strategy
TL;DR: The mechanisms by which tumor cells co-opt the nuclear transport machinery to facilitate carcinogenesis, cell survival, drug resistance, and tumor progression will be elucidated, with a particular focus on the role of the nuclear-cytoplasmic export protein.
Journal ArticleDOI
A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
Albiruni Ryan Abdul Razak,Denis Soulières,Scott A. Laurie,Sebastien J. Hotte,Sardar Singh,Eric Winquist,Stephen Chia,C. Le Tourneau,Phuc Felix Nguyen-Tan,Eric X. Chen,Kelvin K. W. Chan,Tao Wang,N. Giri,Christine Mormont,Susan Quinn,L.L. Siu +15 more
TL;DR: Dacomitinib demonstrated clinical activity in RM-SCCHN and the primary end point of this study was met, and the toxicity profile of this agent was generally manageable with dose interruptions and adjustments.
Journal ArticleDOI
Early phase clinical trials to identify optimal dosing and safety
Natalie Cook,Natalie Cook,Aaron R. Hansen,Aaron R. Hansen,Lillian L. Siu,Lillian L. Siu,Albiruni Ryan Abdul Razak,Albiruni Ryan Abdul Razak +7 more
TL;DR: This review will focus on the limitations to safety and dose determination that have occurred in the development of MTAs and immunotherapies and strategies are proposed to overcome these challenges to develop phase I trials that can more accurately define the recommended dose and identify adverse events.